Name
Azetines
Accession Number
DBCAT001212
Description

Not Available

Drugs
DrugDrug Description
EzetimibeA cholesterol absorption inhibitor used to lower total cholesterol, LDL-C, Apo-B, and non-HDL-C in primary hyperlipidemia and familial cholesterolemia.
XimelagatranFor the treatment of acute deep vein thrombosis.
CobimetinibAn antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma.
AzelnidipineFor the treatment of hypertension.
BaricitinibA Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist.
PF-04418948Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).
RRx-001RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
ItacitinibItacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.
SiponimodA medication used to treat relapsing multiple sclerosis.
PF-03635659Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Atecegatran metoxilAtecegatran metoxil has been used in trials studying the basic science and prevention of Nonvalvular Atrial Fibrillation, Persistent or Permanent Nonvalvular Atrial Fibrillation, and Persistent or Permanent Non-valvular Atrial Fibrillation.
JNJ-41443532JNJ-41443532 has been used in trials studying the basic science and treatment of Diabetes Mellitus, Type 2.
MelagatranNot Annotated
AZD-1656AZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).
PF-5190457PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).
AclimostatAclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes).
CeralifimodCeralifimod is under investigation in clinical trial NCT01226745 (Phase 2 Extension Trial in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)).
Drugs & Drug Targets
DrugTargetType
EzetimibeNiemann-Pick C1-like protein 1target
EzetimibeAminopeptidase Ntarget
EzetimibeSterol O-acyltransferase 1target
EzetimibeUDP-glucuronosyltransferase 1-1enzyme
EzetimibeUDP-glucuronosyltransferase 1-3enzyme
EzetimibeP-glycoprotein 1transporter
EzetimibeCanalicular multispecific organic anion transporter 1transporter
EzetimibeSolute carrier organic anion transporter family member 1B1transporter
EzetimibeUDP-glucuronosyltransferase 2B15enzyme
EzetimibeUDP-glucuronosyltransferase 2B7enzyme
EzetimibeCytochrome P450 3A4enzyme
EzetimibeCanalicular multispecific organic anion transporter 2transporter
EzetimibeATP-binding cassette sub-family G member 2transporter
EzetimibeCytochrome P450 2C8enzyme
EzetimibeBile salt export pumptransporter
XimelagatranProthrombintarget
XimelagatranCytochrome P450 2C9enzyme
CobimetinibDual specificity mitogen-activated protein kinase kinase 1target
CobimetinibCytochrome P450 3A4enzyme
CobimetinibP-glycoprotein 1enzyme
CobimetinibSolute carrier organic anion transporter family member 1B1transporter
CobimetinibSolute carrier organic anion transporter family member 1B3transporter
CobimetinibATP-binding cassette sub-family G member 2transporter
CobimetinibP-glycoprotein 1transporter
AzelnidipineCytochrome P450 3A4enzyme
AzelnidipineVoltage-dependent L-type calcium channel subunit beta-1target
BaricitinibSolute carrier family 22 member 8transporter
BaricitinibATP-binding cassette sub-family G member 2transporter
BaricitinibMultidrug and toxin extrusion protein 2transporter
BaricitinibCytochrome P450 3A4enzyme
BaricitinibTyrosine-protein kinase JAK1target
BaricitinibTyrosine-protein kinase JAK2target
BaricitinibSolute carrier family 22 member 6transporter
BaricitinibSolute carrier family 22 member 2transporter
BaricitinibSolute carrier organic anion transporter family member 1B3transporter
BaricitinibProtein-tyrosine kinase 2-betatarget
BaricitinibTyrosine-protein kinase JAK3target
BaricitinibP-glycoprotein 1transporter
SiponimodSphingosine 1-phosphate receptor 5target
SiponimodSphingosine 1-phosphate receptor 1target
SiponimodCytochrome P450 3A4enzyme
SiponimodCytochrome P450 2C9enzyme